STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study
Eli Lilly announced that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study.
Missouri Attorney General Catherine Hanaway has issued a cease-and-desist letter to pharmaceutical giant Eli Lilly, urging the company to cease requiring hospitals seeking 340B drug discounts to provide claims data, indicating a growing trend of states challenging such practices by drug manufacturers. The letter, sent on October 26th, alleged that Lilly has breached its commitment to provide its medications under the 340B Drug Pricing Program to eligible hospitals in the state.
Hanaway contended that the drugmaker had made "false and misleading statements" and violated state law. She cited University of Missouri Health Care, which operates seven hospitals in the state and reportedly agreed to provide claims data, yet allegedly denied the hospital discounts on its medications despite the arrangement. Hanaway has given Lilly until November 26th to halt its new policy. For the complete story, continue to STAT+.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
